Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 27, Issue 1, 2013, Pages 87-91

  Iwao, Tadashi ^a   Sakai, Kenji ^a   Sata, Michio ^b  

^a Iwao Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C peptide; Liraglutide; Type 2 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84872499566     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2012.07.001     Document Type: Article

References (24)

1. H. Agersø, L.B. Jensen, B. Elbrønd, P. Rolan, and M. Zdravkovic The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195 202
2. C.W. Chia, and J.M. Egan Incretin-based therapies in type 2 diabetes mellitus The Journal of Clinical Endocrinology and Metabolism 93 2008 3703 3716
3. A.M. Covic, J.R. Schelling, M. Constantiner, S.K. Iyengar, and J.R. Sedor Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients Kidney International 58 2000 1742 1750
4. S.N. Davis, D. Johns, D. Maggs, H. Xu, J.H. Northrup, and R.G. Brodows Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents Diabetes Care. 30 2007 2767 2772
5. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
6. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans The Journal of Clinical Investigation 101 1998 515 520
7. J.E. Foley, and S. Sreenan Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes Hormone and Metabolic Research 41 2009 905 909
8. A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, I. Olvera-Alvarez, P.M. Hale, M. Zdravkovic, B. Bode LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherpy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
9. B.J. Hoogwerf, J.J. Barbosa, J.P. Bantle, D. Laine, and F.C. Goetz Urinary C-peptide as a measure of beta-cell function after a mixed meal in healthy subjects: comparison of four-hour urine C-peptide with serum insulin and plasma C-peptide Diabetes Care 6 1983 488 492
10. E. Imai, M. Horio, K. Nitta, K. Yamagata, K. Iseki, S. Hara, N. Ura, Y. Kiyohara, H. Hirakata, T. Watanabe, T. Moriyama, Y. Ando, D. Inaguma, I. Narita, H. Iso, K. Wakai, Y. Yasuda, Y. Tsukamoto, S. Ito, H. Makino, A. Hishida, and S. Matsuo Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease Clinical and Experimental Nephrology 11 2007 41 50
11. M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha, M. Zdravkovic, M. Düring, D.R. Matthews LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes Diabetes Care 32 2009 84 90
12. Prospective Studies Collaboration Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies Lancet 373 2009 1083 1096
13. J.Q. Purnell, J.E. Hokanson, S.M. Marcovina, M.W. Steffes, P.A. Cleary, and J.D. Brunzell Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT Journal of the American Medical Association 280 1998 140 146
14. J. Rosenstock, and V. Fonseca Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Diabetes Care 30 2007 2972 2973
15. D. Russell-Jones, and R. Khan Insulin-associated weight gain in diabetes-causes, effects and coping strategies Diabetes, Obesity and Metabolism 9 2007 799 812
16. Y. Seino, M.F. Rasmussen, M. Zdravkovic, and K. Kaku Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes Diabetes Research and Clinical Practice 81 2008 161 168
17. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes The New England of Journal of Medicine 358 2008 2545 2559
18. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes The New England of Journal of Medicine 358 2008 2560 2572
19. C. Torn C-peptide and autoimmune markers in diabetes Clinical Laboratory 49 2003 1 10
20. E.B. Tsai, N.A. Sherry, J.P. Palmer, and K.C. Herold The rise and fall of insulinsecretion in type 1 diabetes mellitus Diabetologia 49 2006 261 270
21. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group Journal of the American Medical Association 281 1999 2005 2012
22. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
23. E. Van Cauter, F. Mestrez, J. Sturis, and K.S. Polonsky Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance Diabetes 41 1992 368 377
24. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet. 359 2002 824 830